Phaseline

Targets › AHR

AHR (Aryl hydrocarbon receptor): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 2 Phase 2, 2 Phase 3; Immunology; next expected readout Aug 2027.

Ligand-activated transcription factor that enables cells to adapt to changing conditions by sensing compounds from the environment, diet, microbiome and cellular metabolism, and which plays important roles in development, immunity and cancer. Upon ligand binding, translocates into the nucleus, where it heterodimerizes with ARNT and induces transcription by binding to xenobiotic response elements (XRE). (UniProt, P35869)

Open in Phaseline: the race on AHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Organon andTapinarof
Aryl hydrocarbon receptor agonist
AHRPhase 3Plaque Psoriasis; Atopic Dermatitis; Palmoplantar KeratodermaAug 2027
Birch BioMedFS2
Kynurenic acid, aryl hydrocarbon receptor (AhR) agonist
AHRPhase 2Burn ScarSep 2027

Conditions

Burn Scar (1) Plaque Psoriasis (1) Atopic Dermatitis (1) Palmoplantar Keratoderma (1)

Modalities

small molecule (2)

Companies

Birch BioMed (1) Organon and (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.